Location Directory

Clinical trials in Minneapolis, Minnesota

This page shows live ClinicalTrials.gov search results for Minneapolis, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7875

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Pericarditis, Pericarditis Acute, Recurrent Pericarditis
Interventions: KPL-387, Placebo; Drug
Lead sponsor: Kiniksa Pharmaceuticals International, plc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 33
States / cities: Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 27 more

Conditions: Fever, Temperature Monitoring
Interventions: Moni-Patch Temperature Monitoring Patch System, Continuous Tympanic Temperature Monitoring System; Device
Lead sponsor: Murata Vios, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 165
States / cities: Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 132 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: BI 770371, Pembrolizumab, Cetuximab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Louisville, Kentucky • Minneapolis, Minnesota • Columbus, Ohio

Conditions: Glycogen Storage Disease Type II, Pompe Disease
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2034
U.S. locations: 98
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more

Conditions: Atrial Fibrillation
Interventions: High intensity interval training, Moderate intensity continuous training, No Exercise; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Aging, Postural Balance, Motor Adaptation
Interventions: Transcranial Magnetic Stimulation Assessment, Reactive Balance Adaptation Task; Device · Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 95 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Stomatitis
Interventions: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 41
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 37 more

Conditions: Malignant Solid Tumors
Interventions: TAK-505; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 15
States / cities: Orange, California • San Diego, California • San Francisco, California + 10 more

Conditions: Hair Thinning
Interventions: Nutraceuticals (Prototype); Dietary Supplement
Lead sponsor: Unilever R&D; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Fabry Disease
Interventions: ST-920; Biological
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 9
States / cities: Irvine, California • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 136
States / cities: Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 115 more

Clinical trials in Minneapolis, Minnesota

Filter and sort this location

Live official records

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

Accuracy of Moni-Patch Compared With Tympanic Temperature Monitoring in Adults at Risk of Fever

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

Pompe Disease Registry Protocol

High-Intensity Aerobic Lifelong Training--AF

Cerebello-Cortical Connectivity and Balance Adaptation in Younger and Older Adults

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

A Study of TAK-505 in Adults With Solid Tumors

Clinical Study to Evaluate the Impact of Nutraceutical Supplements in Participants With Self-Perceived Thinning Hair

Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)